APLS Projected Dividend Yield

Apellis Pharmaceuticals Inc ( NASDAQ : APLS )

Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic compounds to treat diseases through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Pegcetacoplan targets C3, the central protein of the complement cascade. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

20 YEAR PERFORMANCE RESULTS